Global Anti-Venom Market

Anti-Venom Comprehensive Study by Type (Snake Anti-Venom, Scorpion Anti-Venom, Spider Anti-Venom, Others), Mode of Action (Cytotoxic, Neurotoxic, Haemotoxic, Cardiotoxic, Myotoxic, Others), Antivenom (Polyvalent Heterologous Antivenom, Monovalent Heterologous Antivenom, Homologous Antivenom, Small Molecule Anti-Toxins), Species (Snakes, Scorpions, Spiders, Others), End User (Hospitals, Clinics, Ambulatory Surgical Centers, Others) Players and Region - Global Market Outlook to 2028

Anti-Venom Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Antivenom is defined as the medication which is made from antibodies and it is mainly used to treat venomous bites and stings. It is also known as venom antiserum, antivenin, and antivenom immunoglobulin. In the last few years, the number of snake’s bites cases has been increased. For instance, in April 2019, according to an article published by the World Health Organization, each year more than 4.5 to 5.4 million are bitten by a snake. Hence, the increasing number of cases of snake bites across the world and raising awareness of snake bites treatment.

Highlights from Anti-Venom Market Study
AttributesDetails
Study Period2018-2028
Base Year2022
High Growth MarketAsia-Pacific
Largest MarketNorth America
UnitValue (USD Million)


The key Players profiled in the report are Allison Medical, Inc. (United States), Artsana S.p.a. (Italy), B. Braun Melsungen AG (Germany), Becton, Dickinson, and Company (United States), Boston Scientific Corporation (United States), Hamilton Company (United States), Hill-Rom, Inc. (United States), Hu-Friedy Mfg. Co., LLC (United States), Johnson & Johnson Services, Inc. (United States), Medline Industries, Inc. (United States) and Medtronic plc ( Ireland). Additionally, other players that are part of this comprehensive study are Novo Nordisk A/s (Denmark), Owen Mumford, Ltd. (United Kingdom), Roboz Surgical Instrument Co (United States), Smiths Medical, Inc. (United States) and Stryker Corporation (United States.

Geographic Breakdown and Segment Analysis
The Global Anti-Venom market presents a comprehensive analysis of the Anti-Venom market by product type (Snake Anti-Venom, Scorpion Anti-Venom, Spider Anti-Venom and Others), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Global Anti-Venom industry. Investors and Players can easily understand the inherent opportunities and challenges for their products in geographical region of interest. For instance, while the North America holds majority of market share of the Anti-Venom market

Analyst at AMA have segmented the market study of Global Anti-Venom market by Type, Application and Region.

Influencing Trend:
Rising Government Initiative in order to promote the High Quality antivenom treatment

Market Growth Drivers:
Increasing Cases of Snake Bites, and Scorpion Bites and Rising Awareness about Antivenoms and Enhancing Regulatory Framework

Challenges:
Major Concern of High Cost of Anti-Venom Owing to High Production Cost in Some Regions and Problem Related to Lack in Availability of Essential Anti-Venom Stock

Restraints:
Issue Regarding Poor Healthcare System in Low and Middle-Income Countries

Opportunities:
Growing Demand from the Emerging market such as China, India, Brazil, among others

Market Developments Activities:
In March 2, 2021, B. Braun Avitum AG, medical devices and pharmaceutical products manufacturers and service provider partnered with CytoSorbents Corporation, a critical care immunotherapy provider to launch the global co-marketing agreement to promote the use of CytoSorb® with B. Braun's latest OMNI® continuous blood purification platform and OMNIset® Plus bloodline set. This partnerdhip helped company to expand its presence in anti-venom market
In December 2018, the Bengal Chemicals & Pharmaceuticals Ltd (India) company has introduced snake anti-venom maker. Hence, this launch will affect the growth of the market in the future.



The market is highly fragmented with several major players such as Allison Medical, Inc. (United States), Artsana S.p.a. (Italy), B. Braun Melsungen AG (Germany), among others

Key Target Audience
Pharmaceutical Companies, Research and Development (R&D) Companies, Diagnostic Laboratories, Government Research Institutes and Academic Institutes and Universities

Report Objectives / Segmentation Covered

By Type
  • Snake Anti-Venom
  • Scorpion Anti-Venom
  • Spider Anti-Venom
  • Others
By Mode of Action
  • Cytotoxic
  • Neurotoxic
  • Haemotoxic
  • Cardiotoxic
  • Myotoxic
  • Others

By Antivenom
  • Polyvalent Heterologous Antivenom
  • Monovalent Heterologous Antivenom
  • Homologous Antivenom
  • Small Molecule Anti-Toxins

By Species
  • Snakes
  • Scorpions
  • Spiders
  • Others

By End User
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Cases of Snake Bites, and Scorpion Bites
      • 3.2.2. Rising Awareness about Antivenoms and Enhancing Regulatory Framework
    • 3.3. Market Challenges
      • 3.3.1. Major Concern of High Cost of Anti-Venom Owing to High Production Cost in Some Regions
      • 3.3.2. Problem Related to Lack in Availability of Essential Anti-Venom Stock
    • 3.4. Market Trends
      • 3.4.1. Rising Government Initiative in order to promote the High Quality antivenom treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Anti-Venom, by Type, Mode of Action, Antivenom , Species, End User and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Anti-Venom (Value)
      • 5.2.1. Global Anti-Venom by: Type (Value)
        • 5.2.1.1. Snake Anti-Venom
        • 5.2.1.2. Scorpion Anti-Venom
        • 5.2.1.3. Spider Anti-Venom
        • 5.2.1.4. Others
      • 5.2.2. Global Anti-Venom by: Mode of Action (Value)
        • 5.2.2.1. Cytotoxic
        • 5.2.2.2. Neurotoxic
        • 5.2.2.3. Haemotoxic
        • 5.2.2.4. Cardiotoxic
        • 5.2.2.5. Myotoxic
        • 5.2.2.6. Others
      • 5.2.3. Global Anti-Venom by: Species (Value)
        • 5.2.3.1. Snakes
        • 5.2.3.2. Scorpions
        • 5.2.3.3. Spiders
        • 5.2.3.4. Others
      • 5.2.4. Global Anti-Venom by: End User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Clinics
        • 5.2.4.3. Ambulatory Surgical Centers
        • 5.2.4.4. Others
      • 5.2.5. Global Anti-Venom Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Anti-Venom (Volume)
      • 5.3.1. Global Anti-Venom by: Type (Volume)
        • 5.3.1.1. Snake Anti-Venom
        • 5.3.1.2. Scorpion Anti-Venom
        • 5.3.1.3. Spider Anti-Venom
        • 5.3.1.4. Others
      • 5.3.2. Global Anti-Venom by: Mode of Action (Volume)
        • 5.3.2.1. Cytotoxic
        • 5.3.2.2. Neurotoxic
        • 5.3.2.3. Haemotoxic
        • 5.3.2.4. Cardiotoxic
        • 5.3.2.5. Myotoxic
        • 5.3.2.6. Others
      • 5.3.3. Global Anti-Venom by: Species (Volume)
        • 5.3.3.1. Snakes
        • 5.3.3.2. Scorpions
        • 5.3.3.3. Spiders
        • 5.3.3.4. Others
      • 5.3.4. Global Anti-Venom by: End User (Volume)
        • 5.3.4.1. Hospitals
        • 5.3.4.2. Clinics
        • 5.3.4.3. Ambulatory Surgical Centers
        • 5.3.4.4. Others
      • 5.3.5. Global Anti-Venom Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Anti-Venom (Price)
      • 5.4.1. Global Anti-Venom by: Type (Price)
  • 6. Anti-Venom: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allison Medical, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Artsana S.p.a. (Italy)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. B. Braun Melsungen AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Becton, Dickinson, and Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Boston Scientific Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hamilton Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Hill-Rom, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hu-Friedy Mfg. Co., LLC (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Johnson & Johnson Services, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Medline Industries, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Medtronic plc ( Ireland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Anti-Venom Sale, by Type, Mode of Action, Antivenom , Species, End User and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Anti-Venom (Value)
      • 7.2.1. Global Anti-Venom by: Type (Value)
        • 7.2.1.1. Snake Anti-Venom
        • 7.2.1.2. Scorpion Anti-Venom
        • 7.2.1.3. Spider Anti-Venom
        • 7.2.1.4. Others
      • 7.2.2. Global Anti-Venom by: Mode of Action (Value)
        • 7.2.2.1. Cytotoxic
        • 7.2.2.2. Neurotoxic
        • 7.2.2.3. Haemotoxic
        • 7.2.2.4. Cardiotoxic
        • 7.2.2.5. Myotoxic
        • 7.2.2.6. Others
      • 7.2.3. Global Anti-Venom by: Species (Value)
        • 7.2.3.1. Snakes
        • 7.2.3.2. Scorpions
        • 7.2.3.3. Spiders
        • 7.2.3.4. Others
      • 7.2.4. Global Anti-Venom by: End User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Clinics
        • 7.2.4.3. Ambulatory Surgical Centers
        • 7.2.4.4. Others
      • 7.2.5. Global Anti-Venom Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Anti-Venom (Volume)
      • 7.3.1. Global Anti-Venom by: Type (Volume)
        • 7.3.1.1. Snake Anti-Venom
        • 7.3.1.2. Scorpion Anti-Venom
        • 7.3.1.3. Spider Anti-Venom
        • 7.3.1.4. Others
      • 7.3.2. Global Anti-Venom by: Mode of Action (Volume)
        • 7.3.2.1. Cytotoxic
        • 7.3.2.2. Neurotoxic
        • 7.3.2.3. Haemotoxic
        • 7.3.2.4. Cardiotoxic
        • 7.3.2.5. Myotoxic
        • 7.3.2.6. Others
      • 7.3.3. Global Anti-Venom by: Species (Volume)
        • 7.3.3.1. Snakes
        • 7.3.3.2. Scorpions
        • 7.3.3.3. Spiders
        • 7.3.3.4. Others
      • 7.3.4. Global Anti-Venom by: End User (Volume)
        • 7.3.4.1. Hospitals
        • 7.3.4.2. Clinics
        • 7.3.4.3. Ambulatory Surgical Centers
        • 7.3.4.4. Others
      • 7.3.5. Global Anti-Venom Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Anti-Venom (Price)
      • 7.4.1. Global Anti-Venom by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Anti-Venom: by Type(USD Million)
  • Table 2. Anti-Venom Snake Anti-Venom , by Region USD Million (2017-2022)
  • Table 3. Anti-Venom Scorpion Anti-Venom , by Region USD Million (2017-2022)
  • Table 4. Anti-Venom Spider Anti-Venom , by Region USD Million (2017-2022)
  • Table 5. Anti-Venom Others , by Region USD Million (2017-2022)
  • Table 6. Anti-Venom: by Mode of Action(USD Million)
  • Table 7. Anti-Venom Cytotoxic , by Region USD Million (2017-2022)
  • Table 8. Anti-Venom Neurotoxic , by Region USD Million (2017-2022)
  • Table 9. Anti-Venom Haemotoxic , by Region USD Million (2017-2022)
  • Table 10. Anti-Venom Cardiotoxic , by Region USD Million (2017-2022)
  • Table 11. Anti-Venom Myotoxic , by Region USD Million (2017-2022)
  • Table 12. Anti-Venom Others , by Region USD Million (2017-2022)
  • Table 13. Anti-Venom: by Species(USD Million)
  • Table 14. Anti-Venom Snakes , by Region USD Million (2017-2022)
  • Table 15. Anti-Venom Scorpions , by Region USD Million (2017-2022)
  • Table 16. Anti-Venom Spiders , by Region USD Million (2017-2022)
  • Table 17. Anti-Venom Others , by Region USD Million (2017-2022)
  • Table 18. Anti-Venom: by End User(USD Million)
  • Table 19. Anti-Venom Hospitals , by Region USD Million (2017-2022)
  • Table 20. Anti-Venom Clinics , by Region USD Million (2017-2022)
  • Table 21. Anti-Venom Ambulatory Surgical Centers , by Region USD Million (2017-2022)
  • Table 22. Anti-Venom Others , by Region USD Million (2017-2022)
  • Table 23. South America Anti-Venom, by Country USD Million (2017-2022)
  • Table 24. South America Anti-Venom, by Type USD Million (2017-2022)
  • Table 25. South America Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 26. South America Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 27. South America Anti-Venom, by Species USD Million (2017-2022)
  • Table 28. South America Anti-Venom, by End User USD Million (2017-2022)
  • Table 29. Brazil Anti-Venom, by Type USD Million (2017-2022)
  • Table 30. Brazil Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 31. Brazil Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 32. Brazil Anti-Venom, by Species USD Million (2017-2022)
  • Table 33. Brazil Anti-Venom, by End User USD Million (2017-2022)
  • Table 34. Argentina Anti-Venom, by Type USD Million (2017-2022)
  • Table 35. Argentina Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 36. Argentina Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 37. Argentina Anti-Venom, by Species USD Million (2017-2022)
  • Table 38. Argentina Anti-Venom, by End User USD Million (2017-2022)
  • Table 39. Rest of South America Anti-Venom, by Type USD Million (2017-2022)
  • Table 40. Rest of South America Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 41. Rest of South America Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 42. Rest of South America Anti-Venom, by Species USD Million (2017-2022)
  • Table 43. Rest of South America Anti-Venom, by End User USD Million (2017-2022)
  • Table 44. Asia Pacific Anti-Venom, by Country USD Million (2017-2022)
  • Table 45. Asia Pacific Anti-Venom, by Type USD Million (2017-2022)
  • Table 46. Asia Pacific Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 47. Asia Pacific Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 48. Asia Pacific Anti-Venom, by Species USD Million (2017-2022)
  • Table 49. Asia Pacific Anti-Venom, by End User USD Million (2017-2022)
  • Table 50. China Anti-Venom, by Type USD Million (2017-2022)
  • Table 51. China Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 52. China Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 53. China Anti-Venom, by Species USD Million (2017-2022)
  • Table 54. China Anti-Venom, by End User USD Million (2017-2022)
  • Table 55. Japan Anti-Venom, by Type USD Million (2017-2022)
  • Table 56. Japan Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 57. Japan Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 58. Japan Anti-Venom, by Species USD Million (2017-2022)
  • Table 59. Japan Anti-Venom, by End User USD Million (2017-2022)
  • Table 60. India Anti-Venom, by Type USD Million (2017-2022)
  • Table 61. India Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 62. India Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 63. India Anti-Venom, by Species USD Million (2017-2022)
  • Table 64. India Anti-Venom, by End User USD Million (2017-2022)
  • Table 65. South Korea Anti-Venom, by Type USD Million (2017-2022)
  • Table 66. South Korea Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 67. South Korea Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 68. South Korea Anti-Venom, by Species USD Million (2017-2022)
  • Table 69. South Korea Anti-Venom, by End User USD Million (2017-2022)
  • Table 70. Taiwan Anti-Venom, by Type USD Million (2017-2022)
  • Table 71. Taiwan Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 72. Taiwan Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 73. Taiwan Anti-Venom, by Species USD Million (2017-2022)
  • Table 74. Taiwan Anti-Venom, by End User USD Million (2017-2022)
  • Table 75. Australia Anti-Venom, by Type USD Million (2017-2022)
  • Table 76. Australia Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 77. Australia Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 78. Australia Anti-Venom, by Species USD Million (2017-2022)
  • Table 79. Australia Anti-Venom, by End User USD Million (2017-2022)
  • Table 80. Rest of Asia-Pacific Anti-Venom, by Type USD Million (2017-2022)
  • Table 81. Rest of Asia-Pacific Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 82. Rest of Asia-Pacific Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 83. Rest of Asia-Pacific Anti-Venom, by Species USD Million (2017-2022)
  • Table 84. Rest of Asia-Pacific Anti-Venom, by End User USD Million (2017-2022)
  • Table 85. Europe Anti-Venom, by Country USD Million (2017-2022)
  • Table 86. Europe Anti-Venom, by Type USD Million (2017-2022)
  • Table 87. Europe Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 88. Europe Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 89. Europe Anti-Venom, by Species USD Million (2017-2022)
  • Table 90. Europe Anti-Venom, by End User USD Million (2017-2022)
  • Table 91. Germany Anti-Venom, by Type USD Million (2017-2022)
  • Table 92. Germany Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 93. Germany Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 94. Germany Anti-Venom, by Species USD Million (2017-2022)
  • Table 95. Germany Anti-Venom, by End User USD Million (2017-2022)
  • Table 96. France Anti-Venom, by Type USD Million (2017-2022)
  • Table 97. France Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 98. France Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 99. France Anti-Venom, by Species USD Million (2017-2022)
  • Table 100. France Anti-Venom, by End User USD Million (2017-2022)
  • Table 101. Italy Anti-Venom, by Type USD Million (2017-2022)
  • Table 102. Italy Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 103. Italy Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 104. Italy Anti-Venom, by Species USD Million (2017-2022)
  • Table 105. Italy Anti-Venom, by End User USD Million (2017-2022)
  • Table 106. United Kingdom Anti-Venom, by Type USD Million (2017-2022)
  • Table 107. United Kingdom Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 108. United Kingdom Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 109. United Kingdom Anti-Venom, by Species USD Million (2017-2022)
  • Table 110. United Kingdom Anti-Venom, by End User USD Million (2017-2022)
  • Table 111. Netherlands Anti-Venom, by Type USD Million (2017-2022)
  • Table 112. Netherlands Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 113. Netherlands Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 114. Netherlands Anti-Venom, by Species USD Million (2017-2022)
  • Table 115. Netherlands Anti-Venom, by End User USD Million (2017-2022)
  • Table 116. Rest of Europe Anti-Venom, by Type USD Million (2017-2022)
  • Table 117. Rest of Europe Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 118. Rest of Europe Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 119. Rest of Europe Anti-Venom, by Species USD Million (2017-2022)
  • Table 120. Rest of Europe Anti-Venom, by End User USD Million (2017-2022)
  • Table 121. MEA Anti-Venom, by Country USD Million (2017-2022)
  • Table 122. MEA Anti-Venom, by Type USD Million (2017-2022)
  • Table 123. MEA Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 124. MEA Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 125. MEA Anti-Venom, by Species USD Million (2017-2022)
  • Table 126. MEA Anti-Venom, by End User USD Million (2017-2022)
  • Table 127. Middle East Anti-Venom, by Type USD Million (2017-2022)
  • Table 128. Middle East Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 129. Middle East Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 130. Middle East Anti-Venom, by Species USD Million (2017-2022)
  • Table 131. Middle East Anti-Venom, by End User USD Million (2017-2022)
  • Table 132. Africa Anti-Venom, by Type USD Million (2017-2022)
  • Table 133. Africa Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 134. Africa Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 135. Africa Anti-Venom, by Species USD Million (2017-2022)
  • Table 136. Africa Anti-Venom, by End User USD Million (2017-2022)
  • Table 137. North America Anti-Venom, by Country USD Million (2017-2022)
  • Table 138. North America Anti-Venom, by Type USD Million (2017-2022)
  • Table 139. North America Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 140. North America Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 141. North America Anti-Venom, by Species USD Million (2017-2022)
  • Table 142. North America Anti-Venom, by End User USD Million (2017-2022)
  • Table 143. United States Anti-Venom, by Type USD Million (2017-2022)
  • Table 144. United States Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 145. United States Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 146. United States Anti-Venom, by Species USD Million (2017-2022)
  • Table 147. United States Anti-Venom, by End User USD Million (2017-2022)
  • Table 148. Canada Anti-Venom, by Type USD Million (2017-2022)
  • Table 149. Canada Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 150. Canada Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 151. Canada Anti-Venom, by Species USD Million (2017-2022)
  • Table 152. Canada Anti-Venom, by End User USD Million (2017-2022)
  • Table 153. Mexico Anti-Venom, by Type USD Million (2017-2022)
  • Table 154. Mexico Anti-Venom, by Mode of Action USD Million (2017-2022)
  • Table 155. Mexico Anti-Venom, by Antivenom USD Million (2017-2022)
  • Table 156. Mexico Anti-Venom, by Species USD Million (2017-2022)
  • Table 157. Mexico Anti-Venom, by End User USD Million (2017-2022)
  • Table 158. Anti-Venom Sales: by Type(k Units)
  • Table 159. Anti-Venom Sales Snake Anti-Venom , by Region k Units (2017-2022)
  • Table 160. Anti-Venom Sales Scorpion Anti-Venom , by Region k Units (2017-2022)
  • Table 161. Anti-Venom Sales Spider Anti-Venom , by Region k Units (2017-2022)
  • Table 162. Anti-Venom Sales Others , by Region k Units (2017-2022)
  • Table 163. Anti-Venom Sales: by Mode of Action(k Units)
  • Table 164. Anti-Venom Sales Cytotoxic , by Region k Units (2017-2022)
  • Table 165. Anti-Venom Sales Neurotoxic , by Region k Units (2017-2022)
  • Table 166. Anti-Venom Sales Haemotoxic , by Region k Units (2017-2022)
  • Table 167. Anti-Venom Sales Cardiotoxic , by Region k Units (2017-2022)
  • Table 168. Anti-Venom Sales Myotoxic , by Region k Units (2017-2022)
  • Table 169. Anti-Venom Sales Others , by Region k Units (2017-2022)
  • Table 170. Anti-Venom Sales: by Species(k Units)
  • Table 171. Anti-Venom Sales Snakes , by Region k Units (2017-2022)
  • Table 172. Anti-Venom Sales Scorpions , by Region k Units (2017-2022)
  • Table 173. Anti-Venom Sales Spiders , by Region k Units (2017-2022)
  • Table 174. Anti-Venom Sales Others , by Region k Units (2017-2022)
  • Table 175. Anti-Venom Sales: by End User(k Units)
  • Table 176. Anti-Venom Sales Hospitals , by Region k Units (2017-2022)
  • Table 177. Anti-Venom Sales Clinics , by Region k Units (2017-2022)
  • Table 178. Anti-Venom Sales Ambulatory Surgical Centers , by Region k Units (2017-2022)
  • Table 179. Anti-Venom Sales Others , by Region k Units (2017-2022)
  • Table 180. South America Anti-Venom Sales, by Country k Units (2017-2022)
  • Table 181. South America Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 182. South America Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 183. South America Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 184. South America Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 185. South America Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 186. Brazil Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 187. Brazil Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 188. Brazil Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 189. Brazil Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 190. Brazil Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 191. Argentina Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 192. Argentina Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 193. Argentina Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 194. Argentina Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 195. Argentina Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 196. Rest of South America Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 197. Rest of South America Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 198. Rest of South America Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 199. Rest of South America Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 200. Rest of South America Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 201. Asia Pacific Anti-Venom Sales, by Country k Units (2017-2022)
  • Table 202. Asia Pacific Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 203. Asia Pacific Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 204. Asia Pacific Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 205. Asia Pacific Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 206. Asia Pacific Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 207. China Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 208. China Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 209. China Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 210. China Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 211. China Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 212. Japan Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 213. Japan Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 214. Japan Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 215. Japan Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 216. Japan Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 217. India Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 218. India Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 219. India Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 220. India Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 221. India Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 222. South Korea Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 223. South Korea Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 224. South Korea Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 225. South Korea Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 226. South Korea Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 227. Taiwan Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 228. Taiwan Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 229. Taiwan Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 230. Taiwan Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 231. Taiwan Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 232. Australia Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 233. Australia Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 234. Australia Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 235. Australia Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 236. Australia Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 237. Rest of Asia-Pacific Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 238. Rest of Asia-Pacific Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 239. Rest of Asia-Pacific Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 240. Rest of Asia-Pacific Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 241. Rest of Asia-Pacific Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 242. Europe Anti-Venom Sales, by Country k Units (2017-2022)
  • Table 243. Europe Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 244. Europe Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 245. Europe Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 246. Europe Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 247. Europe Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 248. Germany Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 249. Germany Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 250. Germany Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 251. Germany Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 252. Germany Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 253. France Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 254. France Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 255. France Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 256. France Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 257. France Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 258. Italy Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 259. Italy Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 260. Italy Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 261. Italy Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 262. Italy Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 263. United Kingdom Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 264. United Kingdom Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 265. United Kingdom Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 266. United Kingdom Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 267. United Kingdom Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 268. Netherlands Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 269. Netherlands Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 270. Netherlands Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 271. Netherlands Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 272. Netherlands Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 273. Rest of Europe Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 274. Rest of Europe Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 275. Rest of Europe Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 276. Rest of Europe Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 277. Rest of Europe Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 278. MEA Anti-Venom Sales, by Country k Units (2017-2022)
  • Table 279. MEA Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 280. MEA Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 281. MEA Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 282. MEA Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 283. MEA Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 284. Middle East Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 285. Middle East Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 286. Middle East Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 287. Middle East Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 288. Middle East Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 289. Africa Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 290. Africa Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 291. Africa Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 292. Africa Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 293. Africa Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 294. North America Anti-Venom Sales, by Country k Units (2017-2022)
  • Table 295. North America Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 296. North America Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 297. North America Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 298. North America Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 299. North America Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 300. United States Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 301. United States Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 302. United States Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 303. United States Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 304. United States Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 305. Canada Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 306. Canada Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 307. Canada Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 308. Canada Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 309. Canada Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 310. Mexico Anti-Venom Sales, by Type k Units (2017-2022)
  • Table 311. Mexico Anti-Venom Sales, by Mode of Action k Units (2017-2022)
  • Table 312. Mexico Anti-Venom Sales, by Antivenom k Units (2017-2022)
  • Table 313. Mexico Anti-Venom Sales, by Species k Units (2017-2022)
  • Table 314. Mexico Anti-Venom Sales, by End User k Units (2017-2022)
  • Table 315. Anti-Venom: by Type(USD/Units)
  • Table 316. Company Basic Information, Sales Area and Its Competitors
  • Table 317. Company Basic Information, Sales Area and Its Competitors
  • Table 318. Company Basic Information, Sales Area and Its Competitors
  • Table 319. Company Basic Information, Sales Area and Its Competitors
  • Table 320. Company Basic Information, Sales Area and Its Competitors
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Company Basic Information, Sales Area and Its Competitors
  • Table 324. Company Basic Information, Sales Area and Its Competitors
  • Table 325. Company Basic Information, Sales Area and Its Competitors
  • Table 326. Company Basic Information, Sales Area and Its Competitors
  • Table 327. Anti-Venom: by Type(USD Million)
  • Table 328. Anti-Venom Snake Anti-Venom , by Region USD Million (2023-2028)
  • Table 329. Anti-Venom Scorpion Anti-Venom , by Region USD Million (2023-2028)
  • Table 330. Anti-Venom Spider Anti-Venom , by Region USD Million (2023-2028)
  • Table 331. Anti-Venom Others , by Region USD Million (2023-2028)
  • Table 332. Anti-Venom: by Mode of Action(USD Million)
  • Table 333. Anti-Venom Cytotoxic , by Region USD Million (2023-2028)
  • Table 334. Anti-Venom Neurotoxic , by Region USD Million (2023-2028)
  • Table 335. Anti-Venom Haemotoxic , by Region USD Million (2023-2028)
  • Table 336. Anti-Venom Cardiotoxic , by Region USD Million (2023-2028)
  • Table 337. Anti-Venom Myotoxic , by Region USD Million (2023-2028)
  • Table 338. Anti-Venom Others , by Region USD Million (2023-2028)
  • Table 339. Anti-Venom: by Species(USD Million)
  • Table 340. Anti-Venom Snakes , by Region USD Million (2023-2028)
  • Table 341. Anti-Venom Scorpions , by Region USD Million (2023-2028)
  • Table 342. Anti-Venom Spiders , by Region USD Million (2023-2028)
  • Table 343. Anti-Venom Others , by Region USD Million (2023-2028)
  • Table 344. Anti-Venom: by End User(USD Million)
  • Table 345. Anti-Venom Hospitals , by Region USD Million (2023-2028)
  • Table 346. Anti-Venom Clinics , by Region USD Million (2023-2028)
  • Table 347. Anti-Venom Ambulatory Surgical Centers , by Region USD Million (2023-2028)
  • Table 348. Anti-Venom Others , by Region USD Million (2023-2028)
  • Table 349. South America Anti-Venom, by Country USD Million (2023-2028)
  • Table 350. South America Anti-Venom, by Type USD Million (2023-2028)
  • Table 351. South America Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 352. South America Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 353. South America Anti-Venom, by Species USD Million (2023-2028)
  • Table 354. South America Anti-Venom, by End User USD Million (2023-2028)
  • Table 355. Brazil Anti-Venom, by Type USD Million (2023-2028)
  • Table 356. Brazil Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 357. Brazil Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 358. Brazil Anti-Venom, by Species USD Million (2023-2028)
  • Table 359. Brazil Anti-Venom, by End User USD Million (2023-2028)
  • Table 360. Argentina Anti-Venom, by Type USD Million (2023-2028)
  • Table 361. Argentina Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 362. Argentina Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 363. Argentina Anti-Venom, by Species USD Million (2023-2028)
  • Table 364. Argentina Anti-Venom, by End User USD Million (2023-2028)
  • Table 365. Rest of South America Anti-Venom, by Type USD Million (2023-2028)
  • Table 366. Rest of South America Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 367. Rest of South America Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 368. Rest of South America Anti-Venom, by Species USD Million (2023-2028)
  • Table 369. Rest of South America Anti-Venom, by End User USD Million (2023-2028)
  • Table 370. Asia Pacific Anti-Venom, by Country USD Million (2023-2028)
  • Table 371. Asia Pacific Anti-Venom, by Type USD Million (2023-2028)
  • Table 372. Asia Pacific Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 373. Asia Pacific Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 374. Asia Pacific Anti-Venom, by Species USD Million (2023-2028)
  • Table 375. Asia Pacific Anti-Venom, by End User USD Million (2023-2028)
  • Table 376. China Anti-Venom, by Type USD Million (2023-2028)
  • Table 377. China Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 378. China Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 379. China Anti-Venom, by Species USD Million (2023-2028)
  • Table 380. China Anti-Venom, by End User USD Million (2023-2028)
  • Table 381. Japan Anti-Venom, by Type USD Million (2023-2028)
  • Table 382. Japan Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 383. Japan Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 384. Japan Anti-Venom, by Species USD Million (2023-2028)
  • Table 385. Japan Anti-Venom, by End User USD Million (2023-2028)
  • Table 386. India Anti-Venom, by Type USD Million (2023-2028)
  • Table 387. India Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 388. India Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 389. India Anti-Venom, by Species USD Million (2023-2028)
  • Table 390. India Anti-Venom, by End User USD Million (2023-2028)
  • Table 391. South Korea Anti-Venom, by Type USD Million (2023-2028)
  • Table 392. South Korea Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 393. South Korea Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 394. South Korea Anti-Venom, by Species USD Million (2023-2028)
  • Table 395. South Korea Anti-Venom, by End User USD Million (2023-2028)
  • Table 396. Taiwan Anti-Venom, by Type USD Million (2023-2028)
  • Table 397. Taiwan Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 398. Taiwan Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 399. Taiwan Anti-Venom, by Species USD Million (2023-2028)
  • Table 400. Taiwan Anti-Venom, by End User USD Million (2023-2028)
  • Table 401. Australia Anti-Venom, by Type USD Million (2023-2028)
  • Table 402. Australia Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 403. Australia Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 404. Australia Anti-Venom, by Species USD Million (2023-2028)
  • Table 405. Australia Anti-Venom, by End User USD Million (2023-2028)
  • Table 406. Rest of Asia-Pacific Anti-Venom, by Type USD Million (2023-2028)
  • Table 407. Rest of Asia-Pacific Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 408. Rest of Asia-Pacific Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 409. Rest of Asia-Pacific Anti-Venom, by Species USD Million (2023-2028)
  • Table 410. Rest of Asia-Pacific Anti-Venom, by End User USD Million (2023-2028)
  • Table 411. Europe Anti-Venom, by Country USD Million (2023-2028)
  • Table 412. Europe Anti-Venom, by Type USD Million (2023-2028)
  • Table 413. Europe Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 414. Europe Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 415. Europe Anti-Venom, by Species USD Million (2023-2028)
  • Table 416. Europe Anti-Venom, by End User USD Million (2023-2028)
  • Table 417. Germany Anti-Venom, by Type USD Million (2023-2028)
  • Table 418. Germany Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 419. Germany Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 420. Germany Anti-Venom, by Species USD Million (2023-2028)
  • Table 421. Germany Anti-Venom, by End User USD Million (2023-2028)
  • Table 422. France Anti-Venom, by Type USD Million (2023-2028)
  • Table 423. France Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 424. France Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 425. France Anti-Venom, by Species USD Million (2023-2028)
  • Table 426. France Anti-Venom, by End User USD Million (2023-2028)
  • Table 427. Italy Anti-Venom, by Type USD Million (2023-2028)
  • Table 428. Italy Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 429. Italy Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 430. Italy Anti-Venom, by Species USD Million (2023-2028)
  • Table 431. Italy Anti-Venom, by End User USD Million (2023-2028)
  • Table 432. United Kingdom Anti-Venom, by Type USD Million (2023-2028)
  • Table 433. United Kingdom Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 434. United Kingdom Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 435. United Kingdom Anti-Venom, by Species USD Million (2023-2028)
  • Table 436. United Kingdom Anti-Venom, by End User USD Million (2023-2028)
  • Table 437. Netherlands Anti-Venom, by Type USD Million (2023-2028)
  • Table 438. Netherlands Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 439. Netherlands Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 440. Netherlands Anti-Venom, by Species USD Million (2023-2028)
  • Table 441. Netherlands Anti-Venom, by End User USD Million (2023-2028)
  • Table 442. Rest of Europe Anti-Venom, by Type USD Million (2023-2028)
  • Table 443. Rest of Europe Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 444. Rest of Europe Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 445. Rest of Europe Anti-Venom, by Species USD Million (2023-2028)
  • Table 446. Rest of Europe Anti-Venom, by End User USD Million (2023-2028)
  • Table 447. MEA Anti-Venom, by Country USD Million (2023-2028)
  • Table 448. MEA Anti-Venom, by Type USD Million (2023-2028)
  • Table 449. MEA Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 450. MEA Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 451. MEA Anti-Venom, by Species USD Million (2023-2028)
  • Table 452. MEA Anti-Venom, by End User USD Million (2023-2028)
  • Table 453. Middle East Anti-Venom, by Type USD Million (2023-2028)
  • Table 454. Middle East Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 455. Middle East Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 456. Middle East Anti-Venom, by Species USD Million (2023-2028)
  • Table 457. Middle East Anti-Venom, by End User USD Million (2023-2028)
  • Table 458. Africa Anti-Venom, by Type USD Million (2023-2028)
  • Table 459. Africa Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 460. Africa Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 461. Africa Anti-Venom, by Species USD Million (2023-2028)
  • Table 462. Africa Anti-Venom, by End User USD Million (2023-2028)
  • Table 463. North America Anti-Venom, by Country USD Million (2023-2028)
  • Table 464. North America Anti-Venom, by Type USD Million (2023-2028)
  • Table 465. North America Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 466. North America Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 467. North America Anti-Venom, by Species USD Million (2023-2028)
  • Table 468. North America Anti-Venom, by End User USD Million (2023-2028)
  • Table 469. United States Anti-Venom, by Type USD Million (2023-2028)
  • Table 470. United States Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 471. United States Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 472. United States Anti-Venom, by Species USD Million (2023-2028)
  • Table 473. United States Anti-Venom, by End User USD Million (2023-2028)
  • Table 474. Canada Anti-Venom, by Type USD Million (2023-2028)
  • Table 475. Canada Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 476. Canada Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 477. Canada Anti-Venom, by Species USD Million (2023-2028)
  • Table 478. Canada Anti-Venom, by End User USD Million (2023-2028)
  • Table 479. Mexico Anti-Venom, by Type USD Million (2023-2028)
  • Table 480. Mexico Anti-Venom, by Mode of Action USD Million (2023-2028)
  • Table 481. Mexico Anti-Venom, by Antivenom USD Million (2023-2028)
  • Table 482. Mexico Anti-Venom, by Species USD Million (2023-2028)
  • Table 483. Mexico Anti-Venom, by End User USD Million (2023-2028)
  • Table 484. Anti-Venom Sales: by Type(k Units)
  • Table 485. Anti-Venom Sales Snake Anti-Venom , by Region k Units (2023-2028)
  • Table 486. Anti-Venom Sales Scorpion Anti-Venom , by Region k Units (2023-2028)
  • Table 487. Anti-Venom Sales Spider Anti-Venom , by Region k Units (2023-2028)
  • Table 488. Anti-Venom Sales Others , by Region k Units (2023-2028)
  • Table 489. Anti-Venom Sales: by Mode of Action(k Units)
  • Table 490. Anti-Venom Sales Cytotoxic , by Region k Units (2023-2028)
  • Table 491. Anti-Venom Sales Neurotoxic , by Region k Units (2023-2028)
  • Table 492. Anti-Venom Sales Haemotoxic , by Region k Units (2023-2028)
  • Table 493. Anti-Venom Sales Cardiotoxic , by Region k Units (2023-2028)
  • Table 494. Anti-Venom Sales Myotoxic , by Region k Units (2023-2028)
  • Table 495. Anti-Venom Sales Others , by Region k Units (2023-2028)
  • Table 496. Anti-Venom Sales: by Species(k Units)
  • Table 497. Anti-Venom Sales Snakes , by Region k Units (2023-2028)
  • Table 498. Anti-Venom Sales Scorpions , by Region k Units (2023-2028)
  • Table 499. Anti-Venom Sales Spiders , by Region k Units (2023-2028)
  • Table 500. Anti-Venom Sales Others , by Region k Units (2023-2028)
  • Table 501. Anti-Venom Sales: by End User(k Units)
  • Table 502. Anti-Venom Sales Hospitals , by Region k Units (2023-2028)
  • Table 503. Anti-Venom Sales Clinics , by Region k Units (2023-2028)
  • Table 504. Anti-Venom Sales Ambulatory Surgical Centers , by Region k Units (2023-2028)
  • Table 505. Anti-Venom Sales Others , by Region k Units (2023-2028)
  • Table 506. South America Anti-Venom Sales, by Country k Units (2023-2028)
  • Table 507. South America Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 508. South America Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 509. South America Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 510. South America Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 511. South America Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 512. Brazil Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 513. Brazil Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 514. Brazil Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 515. Brazil Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 516. Brazil Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 517. Argentina Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 518. Argentina Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 519. Argentina Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 520. Argentina Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 521. Argentina Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 522. Rest of South America Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 523. Rest of South America Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 524. Rest of South America Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 525. Rest of South America Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 526. Rest of South America Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 527. Asia Pacific Anti-Venom Sales, by Country k Units (2023-2028)
  • Table 528. Asia Pacific Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 529. Asia Pacific Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 530. Asia Pacific Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 531. Asia Pacific Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 532. Asia Pacific Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 533. China Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 534. China Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 535. China Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 536. China Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 537. China Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 538. Japan Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 539. Japan Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 540. Japan Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 541. Japan Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 542. Japan Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 543. India Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 544. India Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 545. India Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 546. India Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 547. India Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 548. South Korea Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 549. South Korea Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 550. South Korea Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 551. South Korea Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 552. South Korea Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 553. Taiwan Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 554. Taiwan Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 555. Taiwan Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 556. Taiwan Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 557. Taiwan Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 558. Australia Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 559. Australia Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 560. Australia Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 561. Australia Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 562. Australia Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 563. Rest of Asia-Pacific Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 564. Rest of Asia-Pacific Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 565. Rest of Asia-Pacific Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 566. Rest of Asia-Pacific Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 567. Rest of Asia-Pacific Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 568. Europe Anti-Venom Sales, by Country k Units (2023-2028)
  • Table 569. Europe Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 570. Europe Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 571. Europe Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 572. Europe Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 573. Europe Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 574. Germany Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 575. Germany Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 576. Germany Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 577. Germany Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 578. Germany Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 579. France Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 580. France Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 581. France Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 582. France Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 583. France Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 584. Italy Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 585. Italy Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 586. Italy Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 587. Italy Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 588. Italy Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 589. United Kingdom Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 590. United Kingdom Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 591. United Kingdom Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 592. United Kingdom Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 593. United Kingdom Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 594. Netherlands Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 595. Netherlands Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 596. Netherlands Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 597. Netherlands Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 598. Netherlands Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 599. Rest of Europe Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 600. Rest of Europe Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 601. Rest of Europe Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 602. Rest of Europe Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 603. Rest of Europe Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 604. MEA Anti-Venom Sales, by Country k Units (2023-2028)
  • Table 605. MEA Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 606. MEA Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 607. MEA Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 608. MEA Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 609. MEA Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 610. Middle East Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 611. Middle East Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 612. Middle East Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 613. Middle East Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 614. Middle East Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 615. Africa Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 616. Africa Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 617. Africa Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 618. Africa Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 619. Africa Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 620. North America Anti-Venom Sales, by Country k Units (2023-2028)
  • Table 621. North America Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 622. North America Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 623. North America Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 624. North America Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 625. North America Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 626. United States Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 627. United States Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 628. United States Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 629. United States Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 630. United States Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 631. Canada Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 632. Canada Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 633. Canada Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 634. Canada Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 635. Canada Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 636. Mexico Anti-Venom Sales, by Type k Units (2023-2028)
  • Table 637. Mexico Anti-Venom Sales, by Mode of Action k Units (2023-2028)
  • Table 638. Mexico Anti-Venom Sales, by Antivenom k Units (2023-2028)
  • Table 639. Mexico Anti-Venom Sales, by Species k Units (2023-2028)
  • Table 640. Mexico Anti-Venom Sales, by End User k Units (2023-2028)
  • Table 641. Anti-Venom: by Type(USD/Units)
  • Table 642. Research Programs/Design for This Report
  • Table 643. Key Data Information from Secondary Sources
  • Table 644. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Anti-Venom: by Type USD Million (2017-2022)
  • Figure 5. Global Anti-Venom: by Mode of Action USD Million (2017-2022)
  • Figure 6. Global Anti-Venom: by Species USD Million (2017-2022)
  • Figure 7. Global Anti-Venom: by End User USD Million (2017-2022)
  • Figure 8. South America Anti-Venom Share (%), by Country
  • Figure 9. Asia Pacific Anti-Venom Share (%), by Country
  • Figure 10. Europe Anti-Venom Share (%), by Country
  • Figure 11. MEA Anti-Venom Share (%), by Country
  • Figure 12. North America Anti-Venom Share (%), by Country
  • Figure 13. Global Anti-Venom: by Type k Units (2017-2022)
  • Figure 14. Global Anti-Venom: by Mode of Action k Units (2017-2022)
  • Figure 15. Global Anti-Venom: by Species k Units (2017-2022)
  • Figure 16. Global Anti-Venom: by End User k Units (2017-2022)
  • Figure 17. South America Anti-Venom Share (%), by Country
  • Figure 18. Asia Pacific Anti-Venom Share (%), by Country
  • Figure 19. Europe Anti-Venom Share (%), by Country
  • Figure 20. MEA Anti-Venom Share (%), by Country
  • Figure 21. North America Anti-Venom Share (%), by Country
  • Figure 22. Global Anti-Venom: by Type USD/Units (2017-2022)
  • Figure 23. Global Anti-Venom share by Players 2022 (%)
  • Figure 24. Global Anti-Venom share by Players (Top 3) 2022(%)
  • Figure 25. Global Anti-Venom share by Players (Top 5) 2022(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Allison Medical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Allison Medical, Inc. (United States) Revenue: by Geography 2022
  • Figure 29. Artsana S.p.a. (Italy) Revenue, Net Income and Gross profit
  • Figure 30. Artsana S.p.a. (Italy) Revenue: by Geography 2022
  • Figure 31. B. Braun Melsungen AG (Germany) Revenue, Net Income and Gross profit
  • Figure 32. B. Braun Melsungen AG (Germany) Revenue: by Geography 2022
  • Figure 33. Becton, Dickinson, and Company (United States) Revenue, Net Income and Gross profit
  • Figure 34. Becton, Dickinson, and Company (United States) Revenue: by Geography 2022
  • Figure 35. Boston Scientific Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 36. Boston Scientific Corporation (United States) Revenue: by Geography 2022
  • Figure 37. Hamilton Company (United States) Revenue, Net Income and Gross profit
  • Figure 38. Hamilton Company (United States) Revenue: by Geography 2022
  • Figure 39. Hill-Rom, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Hill-Rom, Inc. (United States) Revenue: by Geography 2022
  • Figure 41. Hu-Friedy Mfg. Co., LLC (United States) Revenue, Net Income and Gross profit
  • Figure 42. Hu-Friedy Mfg. Co., LLC (United States) Revenue: by Geography 2022
  • Figure 43. Johnson & Johnson Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Johnson & Johnson Services, Inc. (United States) Revenue: by Geography 2022
  • Figure 45. Medline Industries, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 46. Medline Industries, Inc. (United States) Revenue: by Geography 2022
  • Figure 47. Medtronic plc ( Ireland) Revenue, Net Income and Gross profit
  • Figure 48. Medtronic plc ( Ireland) Revenue: by Geography 2022
  • Figure 49. Global Anti-Venom: by Type USD Million (2023-2028)
  • Figure 50. Global Anti-Venom: by Mode of Action USD Million (2023-2028)
  • Figure 51. Global Anti-Venom: by Species USD Million (2023-2028)
  • Figure 52. Global Anti-Venom: by End User USD Million (2023-2028)
  • Figure 53. South America Anti-Venom Share (%), by Country
  • Figure 54. Asia Pacific Anti-Venom Share (%), by Country
  • Figure 55. Europe Anti-Venom Share (%), by Country
  • Figure 56. MEA Anti-Venom Share (%), by Country
  • Figure 57. North America Anti-Venom Share (%), by Country
  • Figure 58. Global Anti-Venom: by Type k Units (2023-2028)
  • Figure 59. Global Anti-Venom: by Mode of Action k Units (2023-2028)
  • Figure 60. Global Anti-Venom: by Species k Units (2023-2028)
  • Figure 61. Global Anti-Venom: by End User k Units (2023-2028)
  • Figure 62. South America Anti-Venom Share (%), by Country
  • Figure 63. Asia Pacific Anti-Venom Share (%), by Country
  • Figure 64. Europe Anti-Venom Share (%), by Country
  • Figure 65. MEA Anti-Venom Share (%), by Country
  • Figure 66. North America Anti-Venom Share (%), by Country
  • Figure 67. Global Anti-Venom: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Allison Medical, Inc. (United States)
  • Artsana S.p.a. (Italy)
  • B. Braun Melsungen AG (Germany)
  • Becton, Dickinson, and Company (United States)
  • Boston Scientific Corporation (United States)
  • Hamilton Company (United States)
  • Hill-Rom, Inc. (United States)
  • Hu-Friedy Mfg. Co., LLC (United States)
  • Johnson & Johnson Services, Inc. (United States)
  • Medline Industries, Inc. (United States)
  • Medtronic plc ( Ireland)
Additional players considered in the study are as follows:
Novo Nordisk A/s (Denmark) , Owen Mumford, Ltd. (United Kingdom) , Roboz Surgical Instrument Co (United States) , Smiths Medical, Inc. (United States) , Stryker Corporation (United States
Select User Access Type

Key Highlights of Report


Nov 2023 219 Pages 81 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Anti-Venom Market Quantitative research analysis
Global Anti-Venom Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Due to pricing constraints we only profile limited players in the study that includes a mix list of leaders and emerging players, however for evaluation of market size the coverage includes 100+ players.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2028
The Study can be customized to meet your requirements. Please connect with our representative, in case you wish to add or remove certain country or profiled players.
  • Major Concern of High Cost of Anti-Venom Owing to High Production Cost in Some Regions
  • Problem Related to Lack in Availability of Essential Anti-Venom Stock

Know More About Global Anti-Venom Market Report?

Have a Query? Click Here

Other Related Reports

Low Molecular Weight Heparin (LMWHs) Comprehensive Study by Type (Enoxaparin, Dalteparin, Tinzaparin, Fraxiparine), Application (Treatment of Venous Thromboembolism, Complications of Pregnancy, Anti-...
$ 3750
Tongkat Ali Powder Comprehensive Study by Type (Tongkat Ali Root Extract Powder, Tongkat Ali Extract Powder, Tongkat Ali Powder, Tongkat Ali Powder Medicine for Sexual Power), Application (Personal U...
$ 3450
Genital Herpes Treatment Comprehensive Study by Type (Acyclovir, Valacyclovir, Famciclovir), Application (HSV-1, HSV-2), Route of Administration (Oral, Topical, Injectable), Distribution Channel (Hos...
$ 3450
Adult Diaper Rash Cream Comprehensive Study by Application (Hospitals and Clinics, Personal Care, Other), Rash (Irritant Dermatitis, Candida Dermatitis, Allergic Dermatitis, Bacterial Dermatitis), Di...
$ 3450
Pediatric Nutrition Ingredients Comprehensive Study by Type (Proteins, Fats and Oils, Carbohydrates, Vitamins and Minerals, Others), Form (Powder, Liquid) Players and Region - Global Market Outlook t...
$ 3500
Everolimus Tablet Comprehensive Study by Type (2.5 mg Tablets, 5 mg Tablets, 7.5 mg Tablets, 10 mg Tablets), Application (Oncology, Organ transplant, Gastrointestinal, Others), Distribution Channel (...
$ 3450